

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genor Biopharma Holdings Limited**  
**嘉和生物藥業(開曼)控股有限公司**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6998)**

**ANNOUNCEMENT**  
**(1) CHANGE OF NON-EXECUTIVE DIRECTOR; AND**  
**(2) CHANGE IN COMPOSITION OF BOARD COMMITTEE**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Ni Lin (“**Dr. Ni**”) has tendered her resignation as a non-executive Director due to her decision to devote more time on her other business commitments, with effect from 29 July 2022. Upon Dr. Ni’s resignation, she also resigned from her role as a member of the audit committee of the Board (the “**Audit Committee**”).

Dr. Ni has confirmed that (i) she has no claim against the Company in respect of her resignation and there is no disagreement between her and the Board; and (ii) there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”) in relation to her resignation.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Ni for her valuable contribution to the Company during her tenure of office as a non-executive Director and a member of the Audit Committee.

**APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

Following the resignation of Dr. Ni, the Board further announces that Mr. Liu Yi (“**Mr. Liu**”) is appointed as a non-executive Director with effect from 29 July 2022.

The biographical details of Mr. Liu are set out below:

Mr. Liu, aged 33, has approximately eight years of experience in biopharmaceutical business consulting and venture investment. Mr. Liu currently serves as an investment director at Shanghai TF Venture Capital Management Co., Ltd (上海泰甫創業投資管理有限公司). From January 2016 to July 2017, Mr. Liu was an associate consultant at IMS Market Research Consulting (Shanghai) Co., Ltd. (艾美仕市場調研諮詢(上海)有限公司). From September 2017 to July 2019, Mr. Liu was a senior associate at Shanghai TF Venture Capital Management Co., Ltd (上海泰甫創業投資管理有限公司). From July 2019 to May 2020, Mr. Liu was an associate at Quan Capital Management (Shanghai) Co., Ltd (泉創企業管理諮詢(上海)有限公司). Mr. Liu holds a Master Degree in Cell Biology from Xiamen University.

Mr. Liu has entered into a letter of appointment as a non-executive Director with the Company for a term of three years. Pursuant to the letter of appointment, Mr. Liu is subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and the articles of association of the Company. Mr. Liu is not entitled to any remuneration and benefits as the non-executive Director of the Company.

As at the date of this announcement, Mr. Liu is not interested or deemed to be interested in any Shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, (i) Mr. Liu does not hold any directorships in any public companies the securities of which are listed on any securities market in Hong Kong and overseas in the past three years, nor any other major appointments or professional qualifications; (ii) Mr. Liu does not hold any other positions in the Company and other members of the Group; and (iii) Mr. Liu is not related to any directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there is no other information relating to the appointment of Mr. Liu that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any matter that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to extend a warm welcome to Mr. Liu on his appointment.

## **CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE**

Following Dr. Ni’s resignation as a non-executive Director, she also resigned from her role as a member of the Audit Committee, Mr. Liu, the newly appointed non-executive Director, is appointed as a member of the Audit Committee, with effect from 29 July 2022.

Accordingly, the Audit Committee comprises Mr. Fung Edwin as the chairman of the Audit Committee, and Mr. Zhou Honghao and Mr. Liu as members of the Audit Committee.

By Order of the Board  
**Genor Biopharma Holdings Limited**  
**Dr. Guo Feng**  
*Chief Executive Officer and Chairman*

Hong Kong, 29 July 2022

*As at the date of this announcement and following the above resignation and appointment of Directors, the Board comprises Dr. GUO Feng (Chief Executive Officer and Chairman) as an executive director; Dr. LYU Dong, Mr. CHEN Yu and Mr. LIU Yi as non-executive directors; and Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive directors.*